Intravenous immunoglobulin as adjuvant therapy for COVID-19: A case report and literature review

Carlos A Flores-Oria, Emilio Saturno, Supriya Ramanathan, Diana J Martinez Castillo, Roshni Kumar, Nelson Ferrer, Afnan Mossaad, Maria E Tellez, Cindy Jon, Sara C Waters and Ricardo A Mosquera

Abstract
Severe acute respiratory syndrome coronavirus 2 has infected and caused the death of an alarming number of individuals worldwide. No specific treatment has been internationally standardized for coronavirus disease 2019 (COVID-19); however, in some cases, intravenous immunoglobulin (IVIG) has been used as adjuvant treatment in critically ill patients with COVID-19 pneumonia. We report a case of a 50-year-old man with severe COVID-19 pneumonia who received 5 days course of IVIG as adjuvant therapy. Invasive respiratory support was avoided. The patient had a successful recovery and was discharged without supplemental oxygen. A high dose of IVIG may improve survival in patients with severe COVID-19 pneumonia. In the current report, we reviewed literature on how IVIG use may improve the early stages of the disease.

Keywords
Coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2, intravenous immunoglobulin, IVIG, hypoxemia

Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent for coronavirus disease 2019 (COVID-19), has infected more than 170 million people and has caused the death of more than 3.6 million globally, as of June 2021. In Panama, more than 379,000 total cases of COVID-19 and more than 6000 total deaths have been confirmed as of June 2021.1

No specific treatment has been internationally standardized for COVID-19. At the time of this case, current therapeutic regimens were in clinical trials. Empirical administration of intravenous immunoglobulin (IVIG) to patients with severe disease was used in a previous outbreak of SARS-CoV in 2002. Although there was no control group, it was believed that IVIG might be an effective therapy.2 IVIG has been used as adjuvant treatment in critically ill patients with COVID-19 with unequal success.3 We report a case of a patient with severe COVID-19 pneumonia who received 5 days course of IVIG as adjuvant therapy with successful outcomes and reviewed the literature on IVIG use in patients with COVID-19. The patient provided written informed consent for patient information and images to be published.

Case
Presentation
A 50-year-old man presented to a hospital in Panama with a history of dyspnea and oxygen saturation of 87%. He had a 1-week history of nasal congestion, cough, sore throat,
rhinorrhea, and fever with chills, which developed 4 days after returning from New Orleans, Louisiana. During his trip, he had exposure to patients with fever and influenza-like symptoms. During this time, the first COVID-19 cases were reported in both Panama and LA.

Clinical course and treatment

Prior to hospitalization, he was treated with azithromycin 500 mg by mouth daily, prednisone 50 mg by mouth once daily, and budesonide/formoterol 160/4.5 µg two inhalations twice a day. In the emergency room, he was started on supplemental oxygen at 4 liters per minute (LPM) via nasal cannula but rapidly deteriorated upon transfer to the ward, requiring up to 15 LPM via a reservoir mask. Initial chest radiography demonstrated bibasilar infiltrates, and computerized tomography of the chest revealed a bilateral crazy-paving pattern. He tested positive for SARS-CoV-2 via nasopharyngeal polymerase chain reaction (PCR). He was started on hydroxychloroquine, oral azithromycin, and intramuscular ceftriaxone. He continued to be hypoxemic despite optimal noninvasive oxygen therapy and prone position. C-reactive protein (CRP), D-dimers, and ferritin were markedly elevated (Table 1). Mechanical ventilation was considered on day 5 of hospitalization, but the patient declined. IVIG was then initiated at 400 mg/kg/day for 5 days (total 25 g). The fever resolved 2 days later. However, he had persistent though less severe hypoxemia requiring 12 LPM of supplemental oxygen and infiltrates on chest radiography. The second course of antibiotics, vancomycin, and quinolone was initiated for suspected secondary bacterial pneumonia.

Resolution

The SARS-CoV-2 nasopharyngeal PCR test was repeated and found to be negative on days 12 and 17 of hospitalization. The patient was gradually weaned off oxygen after 2 weeks and discharged from the hospital after 18 days without supplemental oxygen and mild, but improving, dyspnea.

Discussion

Coronaviruses are enveloped, positive-stranded RNA viruses with spike proteins on their envelope, which resemble a crown under the electron microscope. Spikes are glycoproteins that confer viral identification and virulence and are essential for cellular tropism. SARS-CoV-2 spike protein binds to angiotensin-converting enzyme 2 as the primary host cell receptor, which is highly expressed in type II alveolar cells of the respiratory tract. This interaction would serve as a target for a therapeutic approach such as neutralizing antibodies that could block receptor binding, viral fusion, and hence replication. It is of great curiosity why some people without apparent risk factors develop severe disease. Interestingly, a genome-wide study conducted in Europe implied that individuals with blood group A have high risks for severe respiratory illness. Although our patient was identified with blood group A, this association was unknown at the time and may or may not fully explain our patient’s clinical course.

The clinical entity is assumed to occur in three phases: the viremia phase (0–7 days), acute phase or pneumonia (7–14 days), and the recovery phase (beyond 21 days). Critical immune interaction is believed to occur in the phase of pneumonia. There may be an adequate immune response that suppresses the virus, or there may be dysregulation leading to the reduction of lymphocytes and an increase of pro-inflammatory cytokines and D-dimers. Administration of IVIG during this early phase could halt the progression by enhancing the immune system. In our case, IVIG was administered just before the transition from acute to pneumonia phase, achieving a satisfactory outcome. The availability of IVIG among institutions and their potential effectiveness and safety in critically ill patients has encouraged their use in COVID-19. A review of reported cases is summarized in Table 2.
Table 2. Cases of IVIG use in COVID-19 in the literature.

| Source                  | Patient 1                        | Patient 2                        | Patient 3                        | Shi et al.8 | Ahmed et al.9 | Moeinraeleh et al.10 | Lanza et al.11 | Mohaddi et al.11 |
|-------------------------|----------------------------------|----------------------------------|----------------------------------|-------------|---------------|----------------------|----------------|------------------|
|                         | Age (years) 56                  | Gender M                         | Comorbidities 2 years' history of hypertension | Gender F   | Gender M   | Gender M Crescentic proliferative glomerulonephritis related to COVID-19 | Gender F History of controlled hypothyroidism | Gender F History of hypertension and coronary artery bypass |
|                         | Prior medications Oseltamivir, Azithromycin, Moxifloxacin | Prior medications Valsartan, Felodipine | Prior medications Lopinavir/ritonavir | Ceftriaxone, Piperacillin/tazobactam, Inhaled interferon alfa-2b, Lopinavir/ritonavir, Human granulocyte-colony stimulating factor (G-CSF) | Possible ITP related to COVID-19 | Crescentic proliferative glomerulonephritis related to COVID-19 | History of controlled hypothyroidism | History of hypertension and coronary artery bypass |
|                         | HLOS (days) 16                  | Time of administration DOH 7     | IVIG Dose 25 g/day                | Dose 20 g/day | Dose 1 g/kg | Dose 400 mL | Dose 450 mL | Dose 30 mL |
|                         | Duration 5 days                 | Duration 6 days                  | Concomitant use Methylprednisolone 40 mg/day × 3 days, Plasma exchange total doses on DOH 6,7,9 methylprednisolone 80 mg | Duration 3 days | Duration 1 day | Duration 5 days | Duration 4 days | Duration 5 days |
|                         | Outcome Afebrile on first day of IVIG, Improved clinically | Outcome Afebrile on second day of IVIG, Improved clinically | Outcome Methylprednisolone 40 mg/day × 3 days, Plasma exchange total doses on DOH 6,7,9 methylprednisolone 80 mg | Outcome Plasma exchange × 5 total doses on DOH 6,7,9 methylprednisolone 80 mg | Outcome Platelet improved and bleeding stopped | Outcome Plasma exchange and Methylprednisolone 1 g, then cyclophosphamide | Outcome Respiratory function improved at the end of IVIG therapy | Outcome Improved and extubated on fifth day of IVIG, Discharged 3 weeks later |

(Continued)
| Source          | Patient | Age (years) | Gender | Comorbidities                                                                 | Prior medications                                                                 | HLOS (days) | IVIG Time of administration | Dose | Duration | Concomitant use | Outcome                                                                 |
|-----------------|---------|-------------|--------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-------------|-----------------------------|------|----------|---------------------------|--------------------------------------------------------------------------|
| Assini et al. [13] | Patient 1 | 55          | M      | Demyelinating disease associated with COVID-19, 20 days after admission       | Hydroxychloroquine, Lopinavir/ritonavir, Unifenvir                              | DOH 20      | 0.4 g/kg/day                | 5 days |                       |                           | Improved on fifth day of IVIG                                             |
| Patient 2       | 60      | M           |        | Demyelinating disease associated with COVID-19, 20 days after admission       | Hydroxychloroquine, Lopinavir/ritonavir, Unifenvir, Tocilizumab                   | DOH 20      | 0.4 g/kg/day                | 5 days |                       |                           | Improved on fifth day of IVIG                                             |
| Aljaberi et al. [14] | Patient 3 | 53          | F      | History of common variable immunodeficiency, hypothyroidism, bronchiectasis, Sjögren’s syndrome | Hydroxychloroquine, Lopinavir/ritonavir, Daclizumab, IVIG (routine infusions)    | DOH 1 and DOH 14 | 40 g/day | > 2 |         |                           | Exubated on DOH 13 and discharged the following day after second dose of IVIG |
| Ikuyama et al. [15] | Patient 4 | 76          | F      | Diabetes mellitus, hypertension, and glaucoma                               | Lopinavir/ritonavir, Moxifloxacin, Piperacillin/tazobactam, Vancomycin            | DOH 3       | 5 g/day                     | 6 days |                       |                           | Continued deteriorating towards the end IVIG treatment. Improved with ECMO |

DOH: day of hospitalization; HLOS: hospital length of stay; ITP: idiopathic thrombocytopenic purpura; IVIG: intravenous immunoglobulin.
A high dose of IVIG has improved survival in some patients with severe COVID-19 pneumonia. The majority of case reports have used a high dose of IVIG (25 g/day or 0.4 g/kg/day for 5 days), obtaining positive outcomes. In case series, a high dose of IVIG infusion helped prevent progression of pulmonary involvement contrary to one case in which 5 g/day for 5 days was administered to a woman who further deteriorated, requiring extracorporeal membrane oxygenation. Timing of administration seems to be crucial as well. According to one retrospective study, administration of IVIG within 48 hours of acute decompensation showed a reduction in ventilator use, hospital and intensive care unit length of stay, and mortality compared with past 48 hours. Although a randomized controlled trial using a different protocol with a lower dose and longer time of administration demonstrated no benefits of IVIG therapy, it still supports safety since it did not show increased mortality with its use.

The major component of IVIG is a relatively pure concentrate of polyclonal immunoglobulin G (IgG) derived from pooled human plasma of thousands of donors. In replacement therapy, the mechanism of action consists of neutralization of pathogen, inactivation of toxins, opsonization, boosting B and T cell functions, and complement activation. Anti-inflammatory effects involve neutralization of autoantibodies and pro-inflammatory cytokines, blocking of activated complement and/or adhesion molecules, interference with idiotypic/anti-idiotypic network, and increased autoantibody clearance, among others. Further investigation is needed to see whether any of these functions apply to coronavirus, including SARS-CoV-2.

Various hypothetical mechanisms of IVIGs have been assumed to have therapeutic effects on COVID-19. Antibody-dependent enhancement (development of primed antibodies against prior coronavirus infection) has been proposed as a possible mechanism to explain disparities in severity among countries. Commercial products of unmodified human IVIGs have demonstrated some in vitro cross-reactivity to SARS-CoV-2 and other coronaviruses. The tested preparations originated from donors in the United States and European countries. The presence of antibody reactivity against SARS-CoV-2 S1 protein has been identified in IVIG preparations. Although, a following study revealed no cross-neutralization antibodies against SARS-CoV-2 detected in IVIG during pre-pandemic period, a promising study demonstrated a rapid increase in the concentration of specific neutralizing antibodies among preparations developed during the pandemic year. The functionality of neutralizing antibodies still needs additional investigation and other possible mechanisms, such as anti-inflammatory effects, may be involved. Ameliorating the inflammatory cascade by binding cytokines and other antibodies, complement scavenging, inhibition of innate immune cells and effector T-cell activation, and expansion of Tregs has been proposed but not demonstrated yet.

Unquestionably, immunization would be the best approach to reduce transmission and occurrence of severe cases. However, high dose of IVIG may still play a beneficial role when the disease develops in people who are at risk of progressing to severe COVID-19 pneumonia.

Conclusion
In summary, this case report demonstrated that a high dose of IVIG given in the early stages may help patients with severe COVID-19 pneumonia. However, there is still an unknown universe regarding the functionality, effectiveness, and benefits of IVIG in patients with severe SARS-CoV-2 infection.

Acknowledgements
We thank the Hospital Pacifica Salud staff for its participation in management and supporting this case report.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval
Our institution does not require ethical approval for reporting individual cases or case series.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent
Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article.

ORCID iD
Carlos A Flores-Oria https://orcid.org/0000-0002-9337-6175

References
1. WHO International, 2020, https://covid19.who.int (2021, accessed 4 June 2021).
2. Wang JT, Sheng WH, Fang CT, et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 2004; 10(5): 818–824.
3. Xie Y, Cao S, Dong H, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect 2020; 81(2): 318–356.
4. Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Commun 2020; 11(1): 1620.
5. Ellingham D, Degenhardt F, Bujanda L, et al. Genomewide association study of severe Covid-19 with respiratory failure. New Engl J Med 2020; 383: 1522–1534.
6. Lin L, Lu L, Cao W, et al. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in
patients with viral pneumonia. *Emerg Microbes Infect* 2020; 9(1): 727–732.
7. Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. *Open Forum Infect Dis* 2020; 7(3): 0faa102.
8. Shi H, Zhou C, He P, et al. Successful treatment of plasma exchange followed by intravenous immunoglobulin in a critically ill patient with 2019 novel coronavirus infection. *Int J Antimicrob Agent* 2020; 2020:105974.
9. Ahmed MZ, Khakwani M, Venkatadasari I, et al. Thrombocytopenia as an initial manifestation of Covid-19; case series and literature review. *Br J Haematol* 2020; 189: 1057–1058.
10. Moeinzadeh F, Dezfuli M, Naimi A, et al. Newly diagnosed glomerulonephritis during COVID-19 infection undergoing immunosuppression therapy: a case report. *Iran J Kidney Dis* 2020; 14(3): 239–242.
11. Lanza M, Polistina GE, Imitazione P, et al. Successful intravenous immunoglobulin treatment in severe COVID-19 pneumonia. *Idcases* 2020; 21: e00794.
12. Mohtadi N, Ghaysouri A, Shirazi S, et al. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: a case series. *Virology* 2020; 548: 1–5.
13. Assini A, Benedetti L, Erika S, et al. New clinical manifestation of COVID-19 related Guillain-Barre syndrome highly responsive to intravenous immunoglobulins: two Italian cases. *Neurol Sci* 2020; 41: 1657–1658.
14. Aljaberi R and Wishah K. Positive outcome in a COVID-19 patient with common variable immunodeficiency after IVIG. *Ann Allergy Asthma Immunol* 2021; 126: 90–92.
15. Ikuyama Y, Wada Y, Tateishi K, et al. Successful recovery from critical COVID-19 pneumonia with extracorporeal membrane oxygenation: a case report. *Respir Med Case Rep* 2020; 30: 101113.
16. Cao W, Liu X, Hong K, et al. High-dose intravenous immunoglobulin in severe coronavirus disease 2019: a multicenter retrospective study in China. *Front Immunol* 2021; 12: 627844.
17. Raman RS, Bhagwan Barge V, Anil Kumar D, et al. A phase II safety and efficacy study on prognosis of moderate pneumonia in coronavirus disease 2019 patients with regular intravenous immunoglobulin therapy. *J Infect Dis* 2021; 223(9): 1538–1543.
18. Tabarsi P, Barati S, Jamaati H, et al. Evaluating the effects of intravenous immunoglobulin (IVIg) on the management of severe COVID-19 cases: a randomized controlled trial. *Int Immuno Pharmacol* 2021; 90: 107205.
19. Matucci A, Maggi E and Vultaggio A. Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects. *Front Immunol* 2015; 5: 690.
20. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? *Microbes Infect* 2020; 22(2): 72–73.
21. Diez JM, Romero C and Gajardo R. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. *Immunotherapy* 2020; 12(8): 571–576.
22. Nguyen AA, Habiballah SB, Platt CD, et al. Immunoglobulins in the treatment of COVID-19 infection: proceed with caution! *Clin Immunol* 2020; 216: 108459.
23. Schweiger J, Karbiener M, Aberham C, et al. No SARS-CoV-2 neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic. *J Infect Dis* 2020; 222(12): 1960–1964.
24. Farcet MR, Karbiener M, Schweiger J, et al. Rapidly increasing SARS-CoV-2 neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic. *J Infect Dis*. Epub ahead of print 16 March 2021. DOI: 10.1093/infdis/jiab142.
25. Galeotti C, Kaveri SV and Bayry J. Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19). *Clin Transl Immunology* 2020; 9(10): e01192.